Advertisement
Letter to the Editor| Volume 148, P92-94, May 2021

Immune-related adverse events after a single dose of pembrolizumab

  • Hanne Vos
    Correspondence
    Corresponding author: Oncologische Heelkunde, UZ Leuven, Herestraat 49, 3000 Leuven, Belgium. Fax: +32 (016) 34 68 34.
    Affiliations
    Department of Surgical Oncology, University Hospitals Leuven, Department of Oncology, KU Leuven, Leuven, Belgium
    Search for articles by this author
  • Kathleen Lambein
    Affiliations
    Department of Surgical Oncology, University Hospitals Leuven, Department of Oncology, KU Leuven, Leuven, Belgium
    Search for articles by this author
  • Hans Wildiers
    Affiliations
    Multidisciplinary Breast Centre, University Hospitals Leuven, Belgium

    Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium
    Search for articles by this author
  • Kevin Punie
    Affiliations
    Multidisciplinary Breast Centre, University Hospitals Leuven, Belgium

    Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium
    Search for articles by this author
  • Ann Smeets
    Affiliations
    Department of Surgical Oncology, University Hospitals Leuven, Department of Oncology, KU Leuven, Leuven, Belgium

    Multidisciplinary Breast Centre, University Hospitals Leuven, Belgium
    Search for articles by this author
Published:April 20, 2021DOI:https://doi.org/10.1016/j.ejca.2021.01.048
      Therapies targeting immune checkpoints have become an established treatment option in oncology. However, due to the generalised immunomodulating effects of the immune checkpoint inhibitors (ICIs), a wide range of immune-related adverse events (irAEs) has been described. Most reported irAEs are based on clinical trial data of patients who received several doses of ICI monotherapy or combined with chemotherapy.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. NCI common Terminology criteria for adverse events (CTCAE), version 5.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf.

        • Postow M.A.
        • Sidlow R.
        • Hellmann M.D.
        Immune-related adverse events associated with immune checkpoint blockade.
        N Engl J Med. 2018; 378: 158-168
        • Michot J.M.
        • Bigenwald C.
        • Champiat S.
        • Collins M.
        • Carbonnel F.
        • Postel-Vinay S.
        • et al.
        Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
        Eur J Canc. 2016; : 54 139-148https://doi.org/10.1016/j.ejca.2015.11.016
        • Fuentes-Antrás J.
        • Peinado P.
        • Guevara-Hoyer K.
        • del Arco C.D.
        • Sánchez-Ramón S.
        • Aguado C.
        Fatal autoimmune storm after a single cycle of anti-PD-1 therapy: a case of lethal toxicity but pathological complete response in metastatic lung adenocarcinoma.
        Hematol Oncol Stem Cell Ther. 2020; https://doi.org/10.1016/j.hemonc.2020.04.006
        • Maamari J.
        • Yeung S.C.J.
        • Chaftari P.S.
        Diabetic ketoacidosis induced by a single dose of pembrolizumab.
        Am J Emerg Med. 2019; 37: 376.e1-376.e2https://doi.org/10.1016/j.ajem.2018.10.040
        • Martinez-Calle N.
        • Rodriguezotero P.
        • Villar S.
        • Mejías L.
        • Melero I.
        • Prosper F.
        • et al.
        Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity.
        Haematologica. 2018; 103: e318-e321https://doi.org/10.3324/haematol.2017.185777